# Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia

> **NCT04830943** · PHASE3 · COMPLETED · sponsor: **Assiut University** · enrollment: 250 (actual)

## Conditions studied

- Covid19 Related Anosmia and Aguesia

## Interventions

- **DRUG:** Cerebrolysin

## Key facts

- **NCT ID:** NCT04830943
- **Lead sponsor:** Assiut University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-01
- **Primary completion:** 2021-09-30
- **Final completion:** 2022-10-30
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2023-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04830943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04830943, "Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04830943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*